YC Interview Questions About International Markets

For Indian founders specifically, international market questions are among the most important to prepare for. Getting them wrong costs credibility on market size. Getting them right — with specific local data, honest expansion sequencing, and a clear "why India first" argument — converts your location from a perceived liability into a genuine asset.

Type 1 — For non-US founders: Partners are asking whether your home market is large enough to justify investment on its own, and whether you have a credible path to global scale if the local market is not sufficient alone.

Type 2 — For US founders claiming global expansion: Partners are asking whether you have actually validated international demand or whether you are citing global market size as a number-inflation strategy.

Both types require the same underlying answer quality: specific local data, not global TAM assertions.

"How big is your market in India specifically?"

What partners probe: Whether you can size the local market precisely with local data — not whether you can cite a global software market report.

Framework: Bottom-up calculation from local verified numbers.

"India has approximately 8 lakh independent pharmacies registered with state drug controllers. Our current target is the tier 2 and tier 3 segment — approximately 5 lakh pharmacies outside the 8 major metros. At ₹2,500/month per pharmacy, the serviceable addressable market in that segment is ₹1,500 crore annually — approximately $180M. We are not including metro pharmacies in our TAM because their needs and competitive dynamics are different from our current product."

That answer is specific, locally sourced, and honest about its scope.

"Why start in India instead of the US?"

What partners probe: Whether your India-first strategy is deliberate and logical, or whether it is simply where you happen to be.

Framework: Three-part answer — cost of validation, founder-specific advantage, and transferability of the model.

"Three reasons. First: we can acquire and iterate with Indian pharmacies at 10x lower cost than US pharmacies, which means we can reach product-market fit 10x faster with the same capital. Second: my cofounder's distributor relationships and domain knowledge are specifically Indian — they are our unfair advantage here, and they do not exist in the US. Third: the independent pharmacy problem in India is structurally similar to Southeast Asia, where our year-3 expansion will be. We are validating in India, not because the US market is inaccessible, but because India is the right place to build the model before taking it global."

"Is India big enough on its own, or do you need the US market?"

What partners probe: Whether your business is viable at India-scale or whether it requires US expansion to be venture-fundable.

Framework: Be direct about the math, then contextualize.

"India is big enough at our current price point. 5 lakh target pharmacies at ₹2,500/month is ₹1,500 crore TAM — a venture-scale market on its own. We do not need the US to justify this investment. The Southeast Asia expansion in year 3 is additive — a similar structural problem across 600,000 independent pharmacies in Vietnam, Thailand, and Indonesia — but it is not required for our base case to work."

"What would it take to expand to the US?"

What partners probe: Whether you have thought seriously about what the US expansion actually requires — in team, capital, product changes, and regulatory complexity — or whether you are citing US expansion as a theoretical upside without understanding the cost.

Framework: Name the specific requirements honestly, including the ones that are hard.

"US expansion would require three things we do not currently have. First: a US-licensed pharmacist on the team — FDA regulations around pharmacy software integration require specific compliance we cannot navigate without that. Second: a completely different distribution channel — our WhatsApp group acquisition model does not exist in the US; we would need to find the US equivalent, which is likely pharmacy association relationships. Third: at minimum 18 months after proving the India model at 500+ pharmacies. US expansion before India is at scale would dilute our focus during the period when execution in one market matters most."

"Who are your competitors in international markets?"

What partners probe: Whether your competitive analysis accounts for international incumbents and whether you understand how competition differs by geography.

Framework: Name global competitors, name local competitors, explain how competition differs by geography.

"Globally: Rx30, PioneerRx, and QS/1 are the established US pharmacy software companies. None of them have meaningful India presence — their products require desktop infrastructure that Indian pharmacies do not have and are priced 10-15x above Indian willingness to pay. In India: Marg ERP and Vyapar are the closest, but both require desktop installation and assume tech-literate users. In Southeast Asia: there is no established category leader — the market is more fragmented than India. We track global competitors for architecture and feature inspiration, not as current market competitors."

"What does the Indian pharmacy market look like that is different from the US?"

What partners probe: Whether you understand the structural differences between your home market and the reference market partners are most familiar with — which demonstrates genuine local depth.

Framework: Name 3-4 specific structural differences with data.

"Four key differences. First: scale — India has 8 lakh independent pharmacies versus approximately 20,000 independent pharmacies in the US. Second: ownership structure — 90% of Indian pharmacies are family-run, typically 1-3 people, versus US independents which often have 4-8 staff. Third: supply chain — Indian pharmacy distribution involves 3-4 intermediary layers (manufacturer → C&F agent → distributor → stockist → pharmacy) versus a more consolidated US model. Fourth: payment infrastructure — India's UPI makes digital payment tracking possible at ₹0 marginal cost, which enables our reconciliation features in a way that would be more expensive to build in the US."

"How would you explain the Indian market to a US investor?"

What partners probe: Whether you can translate local market dynamics for a global investor without either dumbing it down or assuming prior knowledge.

Framework: Reference a familiar US concept, then name the specific Indian difference.

"The easiest comparison: India's independent pharmacy market is structurally similar to what the US corner drugstore market looked like in 1985, before CVS and Walgreens consolidated it. Except India's version has 8 lakh pharmacies, a UPI payment infrastructure that did not exist in the 1985 US, and a smartphone penetration that makes mobile-first product architecture viable from day one. The consolidation wave that hit US pharmacy over 30 years is hitting India over 10 years, compressed by digital infrastructure. We are building the software layer that helps independent pharmacies survive and compete in that wave."

Before your interview, verify and memorize the following India-specific market data relevant to your sector:

For Indian consumer markets:

• India smartphone users: approximately 700M (2024)
• Internet users: approximately 900M
• UPI monthly transactions: 13+ billion (2024)
• Tier 2/3 city population: approximately 700M

For Indian B2B markets:

• MSME count: approximately 63 million registered
• GST-registered businesses: approximately 14 million
• Formalized payroll businesses: approximately 8 million
• Independent pharmacy count: approximately 8 lakh

For Indian fintech context:

• Unbanked adult population: declining rapidly, approximately 120M as of 2023
• Digital payment adoption: 40%+ of retail transactions in urban areas
• RBI licensed NBFCs: approximately 10,000

Know the numbers specific to your sector at this level of precision. Citing global market sizes without India-specific data is the most common Indian founder market-sizing mistake in YC interviews.

Mistake 1: Citing global TAM to compensate for a local market that seems small

"The global pharmacy software market is $4.2B" tells a partner nothing about the Indian independent pharmacy opportunity. Bottom-up from Indian market data is always more credible than global reports. If the Indian market is genuinely large enough on its own (which it typically is in most sectors at ₹1,000+ crore), prove it with local numbers.

Mistake 2: Promising US expansion without a credible path

"We will expand to the US in year 2" stated without naming what US expansion actually requires — team, capital, product changes, regulatory compliance — signals that the US expansion claim is a narrative flourish rather than a real plan. Either describe the US expansion path specifically or don't raise it. A credible India-only market size is more fundable than a vague US expansion claim.

Mistake 3: Apologizing for being in India rather than positioning it as an advantage

Some Indian founders frame their India location as a constraint they hope to overcome. The more fundable frame: India as the deliberate starting point for a model that will eventually be global, chosen because it is the cheapest and fastest place to validate the specific product-market fit hypothesis. Your location is an advantage if you describe it as one.